# A Study of SHR-A1811 and Fulvestrant, With or Without HS-10352, in Locally Advanced or Metastatic Breast Cancer Patients

> **NCT06788197** · PHASE1,PHASE2 · NOT_YET_RECRUITING · sponsor: **Henan Cancer Hospital** · enrollment: 52 (estimated)

## Conditions studied

- Breast Cancer
- Locally Advanced or Metastatic Breast Cancer

## Interventions

- **DRUG:** SHR-A1811+ Fulvestrant
- **DRUG:** SHR-A1811+ Fulvestrant+HS-10352

## Key facts

- **NCT ID:** NCT06788197
- **Lead sponsor:** Henan Cancer Hospital
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-03
- **Primary completion:** 2028-03-31
- **Final completion:** 2029-03-31
- **Target enrollment:** 52 (ESTIMATED)
- **Last updated:** 2025-03-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06788197

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06788197, "A Study of SHR-A1811 and Fulvestrant, With or Without HS-10352, in Locally Advanced or Metastatic Breast Cancer Patients". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06788197. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*